Update on Clinical Trials for Macular Degeneration

Scheie Eye Institute, University of Pennsylvania
A doctor reviewing the results of medical tests with a patient.
Learn about some of the new clinical trials for the wet and dry forms of macular degeneration, including details on participation.

Research on age-related macular degeneration (AMD) is rapidly producing new candidate drugs. These are usually discovered or tested first in mice. Next, there is a phase I trial that tests for safety and dose in a small number of patients. If the drug is safe, it may proceed to a phase II trial, usually with approximately one hundred patients, to continue to test safety and begin to assess effectiveness. Finally, a large phase III trial may be conducted to assess effectiveness. If the drug is safe and effective, the FDA may approve it.

AMD patients may wish to consider participating in clinical trials. By doing this you could receive a treatment that may be more effective than currently available options, as well as help future generations of patients.

By doing this you could receive a treatment that may be more effective than currently available options, as well as help future generations of patients.

How to Search for Clinical Trials

Each clinical trial has a list of inclusion and exclusion criteria. A retina specialist can help identify appropriate clinical trials for each patient. The trials may be conducted at one or multiple locations.


Clinical Trials for Wet AMD

The information below represents a sample of the clinical trials for wet AMD.

Lucentis and Eylea

Sustained release versions of Lucentis and Eylea are currently in clinical trials, and they may reduce the frequency of injections to once every 4-6 months. 


For wet AMD, a drug called Fovista is was tested in combination with the current standard of care, which is intraocular injection of the VEGF inhibitors Eylea, Lucentis, or Avastin. VEGF stands for vascular endothelial growth factor, and when this protein is inhibited, it can block the growth of new leaky blood vessels, which can obscure vision and damage the retina.

However, results of a phase II trial from Regeneron showed no benefit when an anti-PDGF drug was added to an anti-VEGF drug. Similarly, Ophthotech announced in August that in a Phase III trial, Fovista, in combination with Eylea or with Avastin, failed to show superiority to Lucentis.


Abicipar is a drug that is injected into the eye to target VEGF. Its potential advantage is longer duration of action in the eye. In a phase II trial, the data suggest it may last as long as 12 weeks. A phase III trial is now underway.

Clinical Trials for Dry AMD

The information below represents a sample of the clinical trials for dry AMD.


While two phase III trials by Genentech targeting the complement protein called factor D in geographic atrophy patients recently failed, a phase II trial by Apellis targeting a different complement protein called C3 showed promising results.


Another complement inhibitor is Zimura. This drug inhibits a different complement protein called complement factor 5. Like Lampalizumab, it is injected into the eye.


An oral drug is Oracea, which is the antibiotic doxycycline, which has anti-inflammatory activities that may be beneficial for patients with geographic atrophy.

Lipoic Acid

Another orally administered pill just entering clinical trials is the antioxidant lipoic acid. This drug was able to protect mice against retinal degeneration in my lab, and is retina-protective in several other preclinical models. This study is funded in part by BrightFocus Foundation.


The decision to enter a clinical trial is a personal one, and should be discussed with your retina specialist. Sometimes it will result in better outcomes for trial participants, and it always helps current and future generations of AMD patients when clinical trial results guide them to the most effective treatments.


This content was first posted on: November 28, 2017

The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.

These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.

Some of the content may be adapted from other sources, which will be clearly identified within the article.

More Like This

  • An eye doctor viewing the retina of a young woman who has Best's disease.

    Best's Disease

    There are several hereditary vision diseases that affect the macula, the central part of the retina that is responsible for providing sharp, clear, straight-ahead vision. One of them, called Best’s disease, is also known as vitelliform macular dystrophy.

    September 30, 2019
  • Medical illustration showing a drusen deposit in the retina. Illustration by Bob Morreale, provide courtesy of BrightFocus Foundation.

    What Causes Macular Drusen?

    Drusen is a German word meaning “geode.” Since they are the defining feature of age-related macular degeneration (AMD), it’s important to understand what causes them to form. Understanding these mechanisms may lead to treatments that decrease the risk of disease progression.

    July 29, 2019
Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me informed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.